

Julian Lindsay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5787223/publications.pdf>

Version: 2024-02-01

32
papers

606
citations

840585

11
h-index

610775

24
g-index

32
all docs

32
docs citations

32
times ranked

816
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Voriconazole in the Current Era of Oral Triazoles: Current Usage and Therapeutic Level Attainment of Voriconazole at a Major Tertiary Cancer Center. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S387-S388.	0.6	0
2	Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation. <i>Leukemia and Lymphoma</i> , 2022, , 1-3.	0.6	2
3	Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 511.e1-511.e10.	0.6	5
4	Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2021, 62, 330-336.	0.6	5
5	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Preâ€transplant predictors of survival, reactivation, and spontaneous clearance. <i>Transplant Infectious Disease</i> , 2021, 23, e13548.	0.7	7
6	Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 297-306.	1.3	11
7	Infection-Related Mortality in Adults and Children Undergoing Allogeneic Hematopoietic Cell Transplantation: An Australian Registry Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 798.e1-798.e10.	0.6	13
8	Dynamics of Epsteinâ€Barr virus on postâ€transplant lymphoproliferative disorders after antithymocyte globulinâ€conditioned allogeneic hematopoietic cell transplant. <i>Transplant Infectious Disease</i> , 2021, 23, e13719.	0.7	3
9	Epsteinâ€Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 635-645.	1.3	18
10	Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. <i>Internal Medicine Journal</i> , 2021, 51, 67-88.	0.5	36
11	SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab502.	0.4	2
12	Oral fludarabine is an effective and convenient alternative to intravenous fludarabine in fludarabine melphalan based reduced intensity conditioning regimens. <i>Bone Marrow Transplantation</i> , 2020, 55, 1638-1641.	1.3	3
13	New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2020, 50, 277-284.	0.5	12
14	Pharmacist review of high-risk haematology outpatients to improve appropriateness of antifungal prophylaxis. <i>International Journal of Clinical Pharmacy</i> , 2020, 42, 1412-1418.	1.0	1
15	<scp>Epsteinâ€Barr</scp> virus related postâ€transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. <i>Reviews in Medical Virology</i> , 2020, 30, e2108.	3.9	13
16	Predictors of CMV Reactivation and Survival in Adult Allogeneic HSCT Recipients without CMV Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S319-S320.	2.0	0
17	Adherence to Antifungal Guidelines in Malignant Hematology Patients: A Review of the Literature. <i>Journal of Pharmacy Technology</i> , 2019, 35, 270-280.	0.5	3
18	Azole antifungals and new targeted therapies for hematological malignancy. <i>Current Opinion in Infectious Diseases</i> , 2019, 32, 538-545.	1.3	49

#	ARTICLE	IF	CITATIONS
19	New Formulation Suba-Itraconazole Prophylaxis in Patients with Haematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S335-S336.	2.0	1
20	1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data. <i>Open Forum Infectious Diseases</i> , 2018, 5, S342-S342.	0.4	1
21	1354. Novel Formulation SUBA-Itraconazole in Fed and Fasted Healthy Volunteers: Expanding the Clinical Utility of the Established Mold Active Agent. <i>Open Forum Infectious Diseases</i> , 2018, 5, S414-S415.	0.4	0
22	Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	25
23	Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3414-3419.	1.3	43
24	Defibrotide Use in Vincristine-induced Hepatic Sinusoidal Obstruction Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 539-541.	0.2	3
25	Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia. <i>Cancer Medicine</i> , 2016, 5, 3606-3614.	1.3	9
26	Complementary and Alternative Medicine Therapy (CAM) Use by Allogeneic BMT Survivorship Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S476.	2.0	0
27	Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3540-3547.	1.3	19
28	Posaconazole Plasma Concentrations during Intravenous to Oral Tablet Crossover: Are Variations Due to Distribution and Metabolism Rather Than Absorption?. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S475-S476.	2.0	1
29	Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 293-295.	0.5	8
30	The development and evaluation of an oncological palliative care deprescribing guideline: the "OncPal deprescribing guideline"™. <i>Supportive Care in Cancer</i> , 2015, 23, 71-78.	1.0	112
31	Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches. <i>Supportive Care in Cancer</i> , 2014, 22, 1113-1119.	1.0	64
32	Structure, Function and Polymorphism of Human Cytosolic Sulfotransferases. <i>Current Drug Metabolism</i> , 2008, 9, 99-105.	0.7	137